{"id":21643,"date":"2016-02-04T22:48:33","date_gmt":"2016-02-05T06:48:33","guid":{"rendered":"http:\/\/lifeboat.com\/blog\/2016\/02\/breaking-an-injectable-hiv-treatment-could-be-ready-by-2017"},"modified":"2017-04-24T22:35:22","modified_gmt":"2017-04-25T05:35:22","slug":"breaking-an-injectable-hiv-treatment-could-be-ready-by-2017","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2016\/02\/breaking-an-injectable-hiv-treatment-could-be-ready-by-2017","title":{"rendered":"BREAKING: An Injectable HIV Treatment Could Be Ready By 2017"},"content":{"rendered":"<p><a class=\"blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/breaking-an-injectable-hiv-treatment-could-be-ready-by-2017.jpg\"><\/a><\/p>\n<p>CytoDyn Inc. <a href=\"http:\/\/www.cytodyn.com\/media\/press-releases\/detail\/220\/cytodyn-announces-hiv-patients-approaching-17-months-of\">announced in a news release last week<\/a> that its ongoing extension study of PRO 140 monotherapy has shown \u201ccomplete viral-load suppression\u201d for well over a year, with some patients approaching 17 months. The phase I trial included 23 patients.<\/p>\n<p>\u201cThe company believes that complete virologic suppression through treatment with a single agent, PRO 140, a safe and efficacious antibody, rather than through the widely used HAART combination therapy, could present a significant opportunity to treat HIV patients. Based on these monotherapy results, the company plans to file a second Phase 3 protocol for PRO 140 monotherapy with the FDA. CytoDyn is currently conducting a pivotal phase 3 trial for PRO 140 as an adjunct therapy with expected commercialization in 2017.\u201d<\/p>\n<p><a href=\"http:\/\/www.cytodyn.com\/media\/press-releases\/detail\/222\/cytodyn-files-request-for-breakthrough-therapy-designation\">On Jan 22, the company filed a request for Breakthrough Therapy Designation<\/a> with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment experienced patients with virologic failure, meaning other medications alone no longer work for them.<\/p>\n<p><a href=\"http:\/\/www.hivequal.org\/hiv-equal-online\/breaking-an-injectable-hiv-treatment-could-be-ready-by-2017\" target=\"_blank\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CytoDyn Inc. announced in a news release last week that its ongoing extension study of PRO 140 monotherapy has shown \u201ccomplete viral-load suppression\u201d for well over a year, with some patients approaching 17 months. The phase I trial included 23 patients. \u201cThe company believes that complete virologic suppression through treatment with a single agent, PRO [\u2026]<\/p>\n","protected":false},"author":367,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1522],"tags":[],"class_list":["post-21643","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-innovation"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/21643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/367"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=21643"}],"version-history":[{"count":2,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/21643\/revisions"}],"predecessor-version":[{"id":51078,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/21643\/revisions\/51078"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=21643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=21643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=21643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}